EIF1B-AS1: A Potential Drug Target and Biomarker (G440952)

Target Name: EIF1B-AS1

NCBI ID: G440952

EIF1B-AS1

Other Name(s): EIF1B antisense RNA 1

EIF1B-AS1: A Potential Drug Target and Biomarker

Introduction

EIF1B-AS1, also known as EIF1B-AS1 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. EIF1B-AS1 is expressed in most tissues and cells, and its levels are regulated by various factors, including gene expression, DNA methylation, and post-transcriptional modifications.

Disease-RelatedExpression

EIF1B-AS1 has been observed to be involved in several diseases, including cancer. For instance, studies have shown that EIF1B-AS1 is abnormally expressed in various types of cancer, such as breast, ovarian, and colorectal cancer. Additionally, eIF1B-AS1 has been associated with cancer-related behaviors, such as cell motility, invasion, and metastasis.

Furthermore, overexpression of EIF1B-AS1 has been shown to promote the development of cancer by inhibiting the tumor suppressor protein, p53. This is because EIF1B-AS1 can bind to p53 and prevent it from activating target genes that are involved in cell growth and apoptosis.

Biomarker Potential

EIF1B-AS1 has also been identified as a potential biomarker for cancer. The expression of EIF1B-AS1 has been shown to be associated with the severity of cancer-related symptoms, such as pain, nausea, and fatigue. Additionally, higher EIF1B-AS1 expression has been associated with poor prognosis in cancer patients.

Drug Target Potential

The potential drug target for EIF1B-AS1 is related to its role in cancer development and progression. Specifically, studies have shown that EIF1B-AS1 can inhibit the effects of chemotherapy drugs, such as doxorubicin, by preventing them from binding to p53. This is because EIF1B-AS1 can bind to p53 and prevent it from activating target genes that are involved in cell growth and apoptosis, thereby inhibiting the effects of chemotherapy drugs.

In addition, EIF1B-AS1 has also been shown to be involved in the regulation of cell cycle progression. Specifically, EIF1B-AS1 has been shown to promote the G1 phase and the S phase of the cell cycle, which are critical for cell growth and development.

Conclusion

In conclusion, EIF1B-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its expression is regulated by various factors, including gene expression, DNA methylation, and post-transcriptional modifications. Furthermore, studies have shown that EIF1B-AS1 is involved in the regulation of cell cycle progression and has been associated with cancer-related behaviors. Therefore, EIF1B-AS1 may be a promising drug target for cancer treatment.

Protein Name: EIF1B Antisense RNA 1

The "EIF1B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF1B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets